Weida Tong Institution Verified

Sourced from institutional research profiles (UAMS TRI or ARA).

◆ ARA Academy

Division Director

National Center for Toxicological Research

faculty

4 h-index 11 pubs 618 cited

Research Areas

Bioinformatics and Genomic Networks Cancer Genomics and Diagnostics Nanoparticles: synthesis and applications Health Policy Implementation Science Advanced Neural Network Applications Meta-analysis and systematic reviews Carcinogens and Genotoxicity Assessment

Links

ORCID Lab Website Research Group

Edit your profile

OverviewAI-generated summary

Weida Tong's research focuses on advancing regulatory science through the application of computational and data-driven methodologies. Tong's work has explored the regulatory landscape of emerging technologies, including nanotechnology and nanoplastics, from a global perspective. Additionally, Tong has investigated the analytical validity of circulating tumor DNA sequencing assays for precision oncology and contributed to establishing best practices for cancer mutation detection using whole-genome and whole-exome sequencing. This work includes the development of community reference samples and data sets for benchmarking these detection methods.

Further research interests include the integration of multi-omics data, utilizing ratio-based quantitative profiling with reference materials. Tong also examines the role of AI-based language models in drug discovery and development, as well as the broader impact of emerging technologies on regulatory science. As Division Director at the National Center for Toxicological Research, Tong leads a research group and maintains an active lab website. Tong has a notable publication record, with 11 total publications and a h-index of 4, and collaborates with researchers such as Joshua Xu, Leihong Wu, William Slikker, and Binsheng Gong, all from the National Center for Toxicological Research.

Metrics

h-index: 4
Publications: 11
Citations: 618

Selected Publications

AI-powered topic modeling: comparing LDA and BERTopic in analyzing opioid-related cardiovascular risks in women (2025) DOI
Is ChatGPT Ready for Public Use in Organ-Specific Drug Toxicity Research? (2025) DOI
Physiological liver microtissue 384-well microplate system for preclinical hepatotoxicity assessment of therapeutic small molecule drugs (2024) DOI
Progress in toxicogenomics to protect human health (2024) DOI
Generation of a drug-induced renal injury list to facilitate the development of new approach methodologies for nephrotoxicity (2024) DOI
Evaluation of QSAR models for predicting mutagenicity: outcome of the Second Ames/QSAR international challenge project (2023) DOI
Measurement and Mitigation of Bias in Artificial Intelligence: A Narrative Literature Review for Regulatory Science (2023) DOI
Quartet DNA reference materials and datasets for comprehensively evaluating germline variant calling performance (2023) DOI
PLM-ARG: antibiotic resistance gene identification using a pretrained protein language model (2023) DOI
A generative adversarial network model alternative to animal studies for clinical pathology assessment (2023) DOI
The Quartet Data Portal: integration of community-wide resources for multiomics quality control (2023) DOI
Author Correction: Quartet RNA reference materials improve the quality of transcriptomic data through ratio-based profiling (2023) DOI
DICTrank: The largest reference list of 1318 human drugs ranked by risk of drug-induced cardiotoxicity using FDA labeling (2023) DOI
Quartet RNA reference materials improve the quality of transcriptomic data through ratio-based profiling (2023) DOI
Correcting batch effects in large-scale multiomics studies using a reference-material-based ratio method (2023) DOI

ARA Academy 2016 ARA Fellow

Dr. Tong's work emphasizes developing bioinformatic tools and methodologies to support FDA research, regulatory science, and personalized medicine. His notable initiatives include the Microarray Quality Control (MAQC) consortium, the Liver Toxicity Knowledge Base (LTKB), in silico drug repositioning for rare disease treatment, and the ArrayTrack suite for pharmacogenomics review.

Policy Impact

Develops bioinformatic tools supporting FDA regulatory science and personalized medicine, anchoring critical federal research infrastructure in Arkansas.